This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BL-1220

BioLineRx Ltd.

Drug Names(s): BL1220, BL 1220

Description: BL-1220 is an orally administered novel composition of sodium alginate.

Deal Structure: BioLineRx and Novartis
In December 2014, BioLineRx announced that it has entered into a multi-year strategic collaboration agreement with Novartis Pharma designed to facilitate development and commercialization of Israeli-sourced drug candidates.Novartis will evaluate projects identified and presented by BioLineRx for co-development and potential future licensing under the collaboration. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept. As part of the agreement, Novartis has made an initial equity investment in BioLineRx of $10 million for 12.8% of BioLineRxs current shares outstanding.

Under the terms of the agreement, Novartis acquired an initial 5,000,000 American Depositary Shares of BioLineRx in a private transaction at a price of $2.00 per share for a total equity investment of $10 million. Novartis will not have any governance rights and has agreed to certain standstill...See full deal structure in Biomedtracker

Partners: Novartis AG


BL-1220 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug